{"disease":{"id":"eos","name":"eos"},"drugs":{"marketed":[{"drug_id":"dupilumab","indication_name":"Eosinophilic esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dupixent","generic_name":"DUPILUMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor subunit alpha","drug_class":"Interleukin-4 Receptor alpha Antagonist [EPC]","quality_score":62,"revenue":"14600","mechanism":"Dupixent blocks the interleukin-4 receptor, a key player in the immune system's inflammatory response."},{"drug_id":"budesonide","indication_name":"Eosinophilic esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmicort Respules","generic_name":"BUDESONIDE","company_name":"AstraZeneca K.K.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"benralizumab","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fasenra","generic_name":"BENRALIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Interleukin-5 receptor subunit alpha","drug_class":"Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":"1800","mechanism":"Fasenra works by binding to the interleukin-5 receptor on eosinophils, triggering their destruction."},{"drug_id":"mepolizumab","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nucala","generic_name":"MEPOLIZUMAB","company_name":"GSK","drug_phase":"marketed","molecular_target":"Interleukin-5","drug_class":"Interleukin-5 Antagonist [EPC]","quality_score":10,"revenue":"1600","mechanism":"Nucala works by binding to interleukin-5, a protein that stimulates the production of eosinophils."},{"drug_id":"hydroxydaunorubicin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mifamurtide","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mepact","generic_name":"MIFAMURTIDE","company_name":"Takeda France SAS","drug_phase":"marketed","molecular_target":"Nucleotide-binding oligomerization domain-containing protein 2","drug_class":"mifamurtide","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"part-c-met097","indication_name":"Treatment of Hypereosinophilic Syndrome (HES)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"imatinib","indication_name":"Chronic eosinophilic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"imatinib","indication_name":"Idiopathic hypereosinophilic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"liposomal-doxorubicin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"reslizumab","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cinqair","generic_name":"RESLIZUMAB","company_name":"Teva Respiratory Llc","drug_phase":"marketed","molecular_target":"Interleukin-5","drug_class":"Interleukin-5 Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Cinqair works by blocking the action of interleukin-5, a protein that promotes the production of eosinophils, which contribute to inflammation in the airways."},{"drug_id":"doxorubicin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"methotrexate","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trexall","generic_name":"methotrexate","company_name":"Generic (originally Lederle Laboratories)","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"Antifolate, DMARD","quality_score":55,"revenue":null,"mechanism":"Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune)."},{"drug_id":"methotrexat","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methotrexat","company_name":"Biocad","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxydaunomycin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nucala","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nucala","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"Interleukin-5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"diethylcarbamazine","indication_name":"Eosinophilic asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caricide","generic_name":"DIETHYLCARBAMAZINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Arachidonate 5-lipoxygenase","drug_class":"Anthelmintic","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"gleevec","indication_name":"Chronic eosinophilic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"gleevec","indication_name":"Idiopathic hypereosinophilic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"cromolyn-sodium","indication_name":"Eosinophilic Esophagitis","indication_type":"pipeline","phase":"Phase 4","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CROMOLYN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Mast cells","drug_class":"Mast cell stabilizer","quality_score":30,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":23,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07102329","title":"BURDEN OF ESOPHAGEAL CANCER IN EOSINOPHILIC ESOPHAGITIS (ESCAPE STUDY)","phase":"","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06948409","title":"NMBA Reversal and Postoperative Urinary Retention","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70000,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT03557060","title":"NUCALA® Special Drug Use Investigation (EGPA, Long-term)","phase":"","overall_status":"COMPLETED","enrollment_count":4115,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03782350","title":"Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":3079,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT04572438","title":"A Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy","phase":"","overall_status":"COMPLETED","enrollment_count":2234,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT05473325","title":"Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Willows Health","has_results":false},{"nct_id":"NCT03955874","title":"Mechanical Ventilation Discontinuation Practices","phase":"","overall_status":"COMPLETED","enrollment_count":1868,"lead_sponsor_name":"Unity Health Toronto","has_results":false},{"nct_id":"NCT02504853","title":"Natural History and Genetics of Food Allergy and Related Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT00026780","title":"Eligibility Screening for a NCI Pediatric Oncology Branch Research Study","phase":"","overall_status":"COMPLETED","enrollment_count":1720,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03546101","title":"Early Detection of Epstein-Barr Virus Related Disease.","phase":"","overall_status":"COMPLETED","enrollment_count":1527,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT03980886","title":"Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University of California, San Diego","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02523118","title":"OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages","phase":"","overall_status":"RECRUITING","enrollment_count":1350,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT00134030","title":"Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1334,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT05691478","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05763121","title":"A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1061,"lead_sponsor_name":"Areteia Therapeutics","has_results":false},{"nct_id":"NCT06443346","title":"Prospective Registry of EoSinophilic esOphagitis","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06092346","title":"A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":999,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT00899275","title":"Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma","phase":"","overall_status":"COMPLETED","enrollment_count":957,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01164241","title":"Natural History of Severe Allergic Inflammation and Reactions","phase":"","overall_status":"COMPLETED","enrollment_count":945,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03696914","title":"Intense Airway Eosinophilia in Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":918,"lead_sponsor_name":"Laval University","has_results":false},{"nct_id":"NCT00852943","title":"Screening Protocol for Genetic Diseases of Allergic Inflammation","phase":"","overall_status":"COMPLETED","enrollment_count":824,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04735289","title":"Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma","phase":"","overall_status":"UNKNOWN","enrollment_count":810,"lead_sponsor_name":"Istituto Ortopedico Rizzoli","has_results":false},{"nct_id":"NCT04049175","title":"Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":810,"lead_sponsor_name":"Chiesi Farmaceutici S.p.A.","has_results":false},{"nct_id":"NCT05194605","title":"Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT00001406","title":"Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06908096","title":"Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT07215728","title":"Machine Learning Applied to EHRs Data of Patients With Sarcoma","phase":"","overall_status":"COMPLETED","enrollment_count":700,"lead_sponsor_name":"University of Milano Bicocca","has_results":false},{"nct_id":"NCT06265870","title":"Specific Versus Empirical Anthelminthic Treatment in Eosinophilia","phase":"NA","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Prince of Songkla University","has_results":false},{"nct_id":"NCT05813288","title":"A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":654,"lead_sponsor_name":"Areteia Therapeutics","has_results":false},{"nct_id":"NCT05778006","title":"Multi-Center Registry for ME/CFS","phase":"","overall_status":"RECRUITING","enrollment_count":650,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT06236542","title":"Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":632,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT06614491","title":"SCOPE - Single-Point Classification Observational Peristomal Evaluation","phase":"","overall_status":"COMPLETED","enrollment_count":605,"lead_sponsor_name":"ConvaTec Inc.","has_results":false},{"nct_id":"NCT03496402","title":"Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT05093101","title":"The Prognostic Value of Serum Biomarkers in Osteosarcoma","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Istituto Ortopedico Rizzoli","has_results":false},{"nct_id":"NCT00346164","title":"Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":588,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT07094594","title":"ARES Trial: Approach to Resection and Evaluation in Severe Diverticulitis","phase":"","overall_status":"COMPLETED","enrollment_count":578,"lead_sponsor_name":"Azienda Sanitaria Locale Napoli 2 Nord","has_results":false},{"nct_id":"NCT04046939","title":"Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":534,"lead_sponsor_name":"Knopp Biosciences","has_results":true},{"nct_id":"NCT06388889","title":"Phase III Long-Term Extension Study With Dexpramipexole","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":509,"lead_sponsor_name":"Areteia Therapeutics","has_results":false},{"nct_id":"NCT06465485","title":"STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":504,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT00840047","title":"Methionine PET/CT Studies In Patients With Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":503,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT07317791","title":"Cough Flow as a Criterion Decannulation Threshold in Prolonged Tracheostomy Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Hongying Jiang, MD","has_results":false},{"nct_id":"NCT03858426","title":"Prospective Multicenter Nationwide Registry of Children With Eosinophilic Esophagitis","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Sociedad Espanola de Gastroenterologia, Hepatologia y Nutricion Pediatrica","has_results":false},{"nct_id":"NCT06002178","title":"Ultrasound Evaluation of the Vascular Anatomy of the Neck to Minimize the Accidental Risk of Vascular Puncture During Percutaneous Tracheostomy","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"University of Padova","has_results":false},{"nct_id":"NCT06344078","title":"Surgical Italian Guide for the Management of Complicated Acute Diverticulitis Emergency Setting (SIGMA-D). A Prospective Observational Multicenter Study on Behalf of the Italian Society of Colorectal Surgery (SICCR).","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Societa Italiana di Chirurgia ColoRettale","has_results":false},{"nct_id":"NCT05328258","title":"Use of GnRHa During Chemotherapy for Fertility Protection","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Kenny Rodriguez-Wallberg","has_results":false},{"nct_id":"NCT04671693","title":"A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT05896891","title":"San Raffaele EoE Biobank","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06283953","title":"Boosting Resources for Tracheostomy Care at Home","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":480,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03410290","title":"Journey of Patients With Vasculitis From First Symptom to Diagnosis","phase":"","overall_status":"COMPLETED","enrollment_count":456,"lead_sponsor_name":"University of Pennsylvania","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}